Liberation of copper from amyloid plaques: making a risk factor useful for Alzheimer's disease treatment
- PMID: 22663067
- DOI: 10.1021/jm3003813
Liberation of copper from amyloid plaques: making a risk factor useful for Alzheimer's disease treatment
Abstract
Alzheimer's disease (AD) is a complex multifactorial syndrome. Metal chelator and Aβ inhibitor are showing promise against AD. In this report, three small hybrid compounds (1, 2, and 3) have been designed and synthesized utilizing salicylaldehyde (SA) based Schiff bases as the chelators and benzothiazole (BT) as the recognition moiety for AD treatment. These conjugates can capture Cu(2+) from Aβ and become dimers upon Cu(2+) coordination and show high efficiency for both Cu(2+) elimination and Aβ assembly inhibition. Besides, the complexes have superoxide dismutase (SOD) activity and significant antioxidant capacity and are capable of decreasing intracellular reactive oxygen species (ROS) and increasing cell viability. All these results indicate that the multifunctional metal complexes which have Aβ specific recognition moiety and metal ion chelating elements show the potential for AD treatment. Therefore, our work will provide new insights into exploration of more potent amyloid inhibitors.
Similar articles
-
Inhibition of Aβ peptide aggregation by ruthenium(II) polypyridyl complexes through copper chelation.J Inorg Biochem. 2021 Nov;224:111591. doi: 10.1016/j.jinorgbio.2021.111591. Epub 2021 Aug 23. J Inorg Biochem. 2021. PMID: 34450410
-
Synthesis and bio-activities of bifunctional tetrahydrosalen Cu (II) chelators with potential efficacy in Alzheimer's disease therapy.J Inorg Biochem. 2024 Oct;259:112636. doi: 10.1016/j.jinorgbio.2024.112636. Epub 2024 Jun 19. J Inorg Biochem. 2024. PMID: 38943843
-
Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.J Am Chem Soc. 2009 Feb 4;131(4):1436-51. doi: 10.1021/ja806062g. J Am Chem Soc. 2009. PMID: 19133767
-
Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease.Chem Soc Rev. 2014 Oct 7;43(19):6701-15. doi: 10.1039/c4cs00026a. Epub 2014 Mar 27. Chem Soc Rev. 2014. PMID: 24671229 Review.
-
Copper and zinc binding to amyloid-beta: coordination, dynamics, aggregation, reactivity and metal-ion transfer.Chembiochem. 2009 Dec 14;10(18):2837-45. doi: 10.1002/cbic.200900321. Chembiochem. 2009. PMID: 19877000 Review.
Cited by
-
Half a century of amyloids: past, present and future.Chem Soc Rev. 2020 Aug 7;49(15):5473-5509. doi: 10.1039/c9cs00199a. Epub 2020 Jul 7. Chem Soc Rev. 2020. PMID: 32632432 Free PMC article. Review.
-
Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease.RSC Adv. 2018 Jun 29;8(42):23780-23804. doi: 10.1039/c8ra03620a. eCollection 2018 Jun 27. RSC Adv. 2018. PMID: 35540246 Free PMC article. Review.
-
Insights Into the Mechanism of Tyrosine Nitration in Preventing β-Amyloid Aggregation in Alzheimer's Disease.Front Mol Neurosci. 2021 Feb 15;14:619836. doi: 10.3389/fnmol.2021.619836. eCollection 2021. Front Mol Neurosci. 2021. PMID: 33658911 Free PMC article.
-
The Role of Copper in Tau-Related Pathology in Alzheimer's Disease.Front Mol Neurosci. 2020 Sep 10;13:572308. doi: 10.3389/fnmol.2020.572308. eCollection 2020. Front Mol Neurosci. 2020. PMID: 33071757 Free PMC article. Review.
-
Discovery of novel melatonin-mydroxyquinoline hybrids as multitarget strategies for Alzheimer's disease therapy.Front Chem. 2024 Apr 16;12:1374930. doi: 10.3389/fchem.2024.1374930. eCollection 2024. Front Chem. 2024. PMID: 38690010 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
